Javier de Castro

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: The PI3K/Akt pathway is involved in many of the mechanisms targeted by these new drugs, thus a better understanding of this crossroad can help to fully exploit the potential benefits of these new agents.

TL;DR: The relevance of oxidative stress, particularly of lipid peroxidation, in cell response with special focus in carcinogenesis and cancer therapy is reviewed that suggests PH-GPx as a potentially important enzyme involved in the control of this processes.

TL;DR: Asking a few simple patient- and family-centered questions may help to inform the decision regarding the best place for end-of-life care and death.